Tecentriq for Non-Small Cell Lung Cancer – Details


( Last Updated : July 6, 2018)
Generic Name:
Atezolizumab
Project Status:
Complete
Therapeutic Area:
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Tecentriq
Project Line:
Reimbursement Review
Project Number:
PC0115-000
NOC Date:

Details


Strength:
60 mg/mL
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer
Funding Request:
For the treatment of patients with locally advanced or metastatic non-small cell lung cancer who have progressed on or after systemic chemotherapy until loss of clinical benefit
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
Check-point meeting (target date):
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.